NeuroMetrix Reports Q2 2023 Business Highlights
July 27, 2023 07:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and six months period ended June 30, 2023. The...
NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call
July 20, 2023 13:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q2 2023 business and financial highlights before the opening of the...
NeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia
July 11, 2023 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expansion of its sales force to drive further adoption of Quell® Fibromyalgia, which is the first...
Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients
June 28, 2023 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of two large studies that support the clinical utility of DPNCheck screening in people...
Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)
May 31, 2023 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted publication of an abstract describing partial results from a NIH-funded, multi-site randomized controlled trial...
NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call
April 28, 2023 09:21 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2023 first quarter financial results before the opening of the market on...
NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting
March 21, 2023 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 - 26 in...
NeuroMetrix Reports Q4 and Full Year 2022 Financial Results
February 23, 2023 07:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2022. The...
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call
February 16, 2023 14:58 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 fourth quarter and year end financial results before the opening of...
NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy
January 23, 2023 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the commercial availability of DPNCheck 2.0, the Company's latest point-of-care device that...